Recent Innovations and Nano-Delivery of Actinium-225: A Narrative Review.

actinium-225 nanotechnology radiopharmaceuticals recoiling of daughters targeted radionuclide therapy

Journal

Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003

Informations de publication

Date de publication:
13 Jun 2023
Historique:
received: 17 04 2023
revised: 13 05 2023
accepted: 12 06 2023
medline: 28 6 2023
pubmed: 28 6 2023
entrez: 28 6 2023
Statut: epublish

Résumé

The actinium-225 (

Identifiants

pubmed: 37376167
pii: pharmaceutics15061719
doi: 10.3390/pharmaceutics15061719
pmc: PMC10304099
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Références

Semin Nucl Med. 2020 Mar;50(2):119-123
pubmed: 32172796
Theranostics. 2022 Oct 17;12(17):7203-7215
pubmed: 36438496
Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):129-138
pubmed: 30232539
Chemistry. 2020 Sep 4;26(50):11435-11440
pubmed: 32588455
Pharmaceutics. 2022 Dec 30;15(1):
pubmed: 36678756
Eur J Nucl Med Mol Imaging. 2022 Aug;49(10):3581-3592
pubmed: 35384462
Tumour Biol. 2012 Jun;33(3):573-90
pubmed: 22143940
Cancer Biother Radiopharm. 2022 Jun;37(5):355-363
pubmed: 35695807
Pharmaceutics. 2020 Feb 21;12(2):
pubmed: 32098286
EJNMMI Radiopharm Chem. 2022 Nov 4;7(1):29
pubmed: 36333648
J Nanopart Res. 2018;20(3):83
pubmed: 29576738
Appl Radiat Isot. 2017 Oct;128:183-189
pubmed: 28734193
Bioorg Med Chem Lett. 2010 Feb 1;20(3):927-31
pubmed: 20045643
Nucl Med Commun. 2015 May;36(5):414-22
pubmed: 25646703
J Clin Endocrinol Metab. 2001 Apr;86(4):1568-73
pubmed: 11297585
Q J Nucl Med Mol Imaging. 2020 Sep;64(3):265-277
pubmed: 32441067
Sci Adv. 2021 Oct 22;7(43):eabk0273
pubmed: 34669462
Am J Clin Oncol. 2012 Apr;35(2):167-77
pubmed: 21127414
Nanomaterials (Basel). 2020 Jul 13;10(7):
pubmed: 32668687
Front Med (Lausanne). 2015 Mar 17;2:12
pubmed: 25853132
Indian J Nucl Med. 2020 Oct-Dec;35(4):299-304
pubmed: 33642753
Materials (Basel). 2021 Aug 24;14(17):
pubmed: 34500873
J Control Release. 2018 Oct 10;287:177-193
pubmed: 30086338
Curr Radiopharm. 2011 Oct;4(4):306-20
pubmed: 22202153
N Engl J Med. 2021 Sep 16;385(12):1091-1103
pubmed: 34161051
Cancer Res. 2003 Aug 15;63(16):5084-90
pubmed: 12941838
Semin Nucl Med. 2020 Mar;50(2):162-170
pubmed: 32172801
Curr Radiopharm. 2018;11(3):192-199
pubmed: 29793418
Pharmaceutics. 2021 May 13;13(5):
pubmed: 34068206
Nat Biotechnol. 2018 Dec 6;36(12):1125-1127
pubmed: 30520873
J Nucl Med. 2015 Jun;56(6):897-900
pubmed: 25931476
Nat Rev Drug Discov. 2020 Sep;19(9):589-608
pubmed: 32728208
Mol Pharm. 2020 Sep 8;17(9):3553-3566
pubmed: 32787284
J Control Release. 2021 Feb 10;330:726-737
pubmed: 33428985
Cell Death Differ. 2002 Jun;9(6):593-4
pubmed: 12032666
Bioconjug Chem. 2007 Nov-Dec;18(6):2061-7
pubmed: 17935286
Anal Chem. 2005 Oct 1;77(19):6288-91
pubmed: 16194090
EJNMMI Radiopharm Chem. 2021 Dec 20;6(1):38
pubmed: 34928478
J Clin Oncol. 2002 May 15;20(10):2453-63
pubmed: 12011122
Cancer Biother Radiopharm. 2018 Oct;33(8):336-348
pubmed: 29889562
Bioconjug Chem. 2011 Sep 21;22(9):1784-92
pubmed: 21851119
Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1393-1407
pubmed: 28451827
Clin Cancer Res. 2022 May 13;28(10):2030-2037
pubmed: 35247915
Nat Commun. 2016 Aug 17;7:12312
pubmed: 27531582
Cancer Biother Radiopharm. 2002 Apr;17(2):219-31
pubmed: 12030116
Cancer Biother Radiopharm. 2020 Aug;35(6):446-458
pubmed: 32302510
Int J Pharm. 2021 Sep 5;606:120870
pubmed: 34245844
Cancer Biother Radiopharm. 2014 Feb;29(1):34-41
pubmed: 24102173
Curr Radiopharm. 2023;16(2):133-139
pubmed: 36464880
Sci Rep. 2019 Aug 12;9(1):11671
pubmed: 31406320
Cancers (Basel). 2021 Apr 20;13(8):
pubmed: 33923965
Indian J Nucl Med. 2021 Apr-Jun;36(2):114-119
pubmed: 34385780
Eur J Nucl Med Mol Imaging. 2022 Sep;49(11):3627-3638
pubmed: 35556158
Lancet Oncol. 2018 Jun;19(6):825-833
pubmed: 29752180
Clin Cancer Res. 2004 Jul 1;10(13):4489-97
pubmed: 15240541
Curr Radiopharm. 2022;15(2):96-103
pubmed: 34250876
Pract Radiat Oncol. 2022 Jul-Aug;12(4):312-316
pubmed: 35717046
Nanomaterials (Basel). 2022 Feb 09;12(4):
pubmed: 35214911
Adv Drug Deliv Rev. 2008 Sep;60(12):1371-82
pubmed: 18514364
Lancet Oncol. 2020 Mar;21(3):e146-e156
pubmed: 32135118
J Nucl Med. 2004 Feb;45(2):253-60
pubmed: 14960644
J Nanobiotechnology. 2019 Aug 21;17(1):90
pubmed: 31434562
Curr Drug Deliv. 2010 Apr;7(2):168-74
pubmed: 20158485
Curr Radiopharm. 2012 Jul;5(3):221-7
pubmed: 22642390
Nucl Med Biol. 2004 May;31(4):441-9
pubmed: 15093814

Auteurs

Sipho Mdanda (S)

Nuclear Medicine Research Infrastructure (NuMeRI), Steve Biko Academic Hospital, Pretoria 0028, South Africa.
Department of Nuclear Medicine, University of Pretoria, Pretoria 0001, South Africa.

Lindokuhle M Ngema (LM)

Wits Advanced Drug Delivery Platform (WADDP) Research Unit, Department of Pharmacy and Pharmacology, School of Therapeutic Sciences, Faculty of Health Sciences, University of the Witwatersrand, 7 York Road, Johannesburg 2193, South Africa.
Johns Hopkins Medicine, Department of Radiation Oncology and Molecular Radiation Sciences, Baltimore, MD 21218, USA.

Amanda Mdlophane (A)

Nuclear Medicine Research Infrastructure (NuMeRI), Steve Biko Academic Hospital, Pretoria 0028, South Africa.
Department of Nuclear Medicine, University of Pretoria, Pretoria 0001, South Africa.

Mike M Sathekge (MM)

Nuclear Medicine Research Infrastructure (NuMeRI), Steve Biko Academic Hospital, Pretoria 0028, South Africa.
Department of Nuclear Medicine, University of Pretoria, Pretoria 0001, South Africa.

Jan Rijn Zeevaart (JR)

Nuclear Medicine Research Infrastructure (NuMeRI), Steve Biko Academic Hospital, Pretoria 0028, South Africa.
Radiochemistry, The South African Nuclear Energy Corporation, Pelindaba, Hartbeespoort 0240, South Africa.

Classifications MeSH